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“American Burn Association Practice Guidelines for Prevention, Diagnosis, and Treatment of Ventilator-Associated
Pneumonia in Burn Patients” was published to provide recommendation for the prevention, diagnosis, and treatment
of ventilator-associated pneumonia in burn patients. This article makes interpretations and conclusions for prevention,
diagnosis and treatment from this guideline in the combination of domestic burn patients.
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Ventilator-Associated Pneumonia (VAP) is an infectious
disease of pulmonary parenchym that occurs 48 hours or
longer after mechanical ventilation by means of endo-
tracheal tubes or tracheostomy. The purpose of “American
Burn Association Practice Guidelines for Prevention, Diag-
nosis, and Treatment of Ventilator-Associated Pneumonia
in Burn Patients” is to review the published literature on
ventilator-associated pneumonia (VAP) in burn patients
[1]. Evidence-based recommendations are provided for the
prevention, diagnosis, and treatment of VAP in adult burn
patients.
Review
The pathogenesis and predisposing factors of VAP
Aspiration from respiratory and gastrointestinal colonized
bacteria
VAP is often induced by microbial invasion of the sterile
lower respiratory tract and lung parenchyma as patients
inhale, and less by bloodstream spread or direct extension
of adjacent infection. The research has demonstrated that
the oropharynx is a potential reservoir for VAP after com-
paring bacterial DNA samples from broncheoalveolar
lavages to organisms present on patients’ tongues [2, 3].* Correspondence: guogh2000@hotmail.com
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(http://creativecommons.org/publicdomain/zeroThe stomach and sinuses are potential reservoirs of bac-
teria as well [4].The stomach often gets colonized with
Gram-negative bacteria during critical illness, and enteric
Gram-negative bacteria are one of the most frequent mi-
croorganisms isolated from cultures of patients with VAP.
Indwelling gastric tubes weaken the function of the
lower esophageal sphincter during mechanical ventila-
tion, resulting in high incidence of gastric reflux and
sustained aspiration which evolve the infection in the
lung parenchyma.Aspiration from secretions of upper respiratory tract
Bypassing the glottis barrier, with aspiration of contami-
nated secretions around the endotracheal tube cuff, in-
tubation and mechanical ventilation weaken the normal
respiratory tract defenses against infection. The patients
with mechanical ventilation are unable to clear their
own secretions, which has impaired mucocilary clear-
ance, and are subjected to repeated infection inspite of
suctioning. The incidence of VAP increases with the
duration of mechanical ventilation. In the early period of
ventilation, the risk of VAP increase fastestly, at an esti-
mated incidence of 3 % per day during the first 5 days,
decreasing to 2 % per day on days 5 to 10, and to 1 %
per day after 10 days [5].article distributed under the terms of the Creative Commons Attribution
by/4.0) which permits unrestricted use, distribution, and reproduction in
operly credited. The Creative Commons Public Domain Dedication waiver
/1.0/) applies to the data made available in this article, unless otherwise stated.
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Burn injury is a strong predisposing factor for VAP.
Nearly 10 to 20 % of burn patients are also sufferers of
inhalation injury, and the risk increases with increasing
burn size [6]. Inhalation injury is a potential signal of
prolonged ventilator dependence, increased duration of
hospitalization, and likelihood of fatality. In the patients
with large burns, increased capillary permeability occurs
not only at the injured sites, but also in remote organs.
Just as the edema in the burn wound, the respiratory
mucosa would develop into edema caused by an inflam-
matory cascade [7]. The exudation of plasma proteins
from the pulmonary microvasculature into the intersti-
tial and alveolar spaces leads to secretion formation
which congeal with neutrophils and necrotic cellular
debris to form fibrin casts, partially or fully obstructing
the airways and causing bronchoconstriction. Induced
by the acute inflammatory response, release of the pro-
teolytic enzymes and oxidants destroys the lung paren-
chyma and increases the microvascular permeability,
further accelerating edema formation and decreasing gas
exchange [8]. Alveloar collapse and decrease in lung
compliance result from diminished surfactant.
In conclusion, burn patients with inhalation injury de-
velop pulmonary complications frequently, including re-
active airway disease, acute respiratory distress syndrome
(ARDS) and pneumonia. VAP is a common complication
of ARDS: about 34 to 70 % of patients with ARDS develop
VAP [9].Autopsy demonstrated that nearly 73 % of pa-
tients with diagnosis of ARDS also have histological evi-
dence of pneumonia [10].
Else predisposing factors
Host factors includes burn/trauma, severe critical illness,
age>60 years, ARDS, chronic obstructive pulmonary dis-
ease, serum albumin<2.2g/dL, multiple organ dysfunction,
large-volume gastric aspiration, gastric colonization, ele-
vated pH, Upper respiratory tract colonization and sinusitis.
Intervention factors includes mechanical ventilation>2 d,
re-intubation, supine head position, paralytic agents, con-
tinuous intravenous sedation, positive end-expiratory pres-
sure, frequent ventilator circuit changes, >4 units of blood
products transfused, histamine 2-blockers, antacids, naso-
gastric tube, prior antibiotic therapy, transport out of the
intensice care unit [11, 12].
Prevention strategies of VAP
Necessity of mechanical ventilation
In General, unnecessary intubation and mechanical ven-
tilation should be avoided as much as possible, because
this process can increase the risk of VAP 6 to 21-fold.
However, when the necessary intubation is needed, it
should be performed under controlled conditions as
much as possible. The research shows that intubationsin emergency department lead to higher incidence of
VAP than in the ICU setting [13]. Furthermore, VAP in-
cidence can be reduced when accidental tube dislodge-
ment and emergency reintubation are avoided. In order
to limit reintubation for laryngeal edema and postextu-
bation stridor, presence of a cuff leak over 10 to 15 %
has been suggested as a simple screnning test whether
reintubation is needed or not, and that is particularly
useful in the burn patients with extensivr head and neck
edema following burn resuscitation. The recent study
has showed that daily interruption of sedation and wean-
ing protocols can not only reduce the duration of mech-
anical ventilation in ICU patients, but also improve the
extubation rates without an increase in reintubation
rates [14].
Specialized endotracheal tubes
Because of reducing the bacterial inoculum, specialized
endotracheal tubes may prove particularly beneficial in
patients with prolonged mechanical ventilation. In sev-
eral studies, tubes with continuous aspiration of subglot-
tic secretions have reduced the incidence of early-onset
VAP [15]. Because of the broad-spectrum antimicrobial
activity of silver, silver impregnated endotracheal tubes
have potential applications in theory. Silver-coated endo-
tracheal tubes were used in a randomized trial of 9417
patients across 54 centers in North America. The results
show that a 35.9 % relative risk reduction in VAP which
reduce the incidence of VAP from 7,5 % to 4.8 % in a
mixed ICU population of patients expected to require
intubation for over 24 hours [16].
Reducing aspiration from gastrointestinal sources
As an increased risk of aspiration of gastric contents, the
administration of enteral nutrition with supine position
are thougt to be a risk factor for the development of
VAP [17]. The research has demonstrated that patients
administrated with enteral nutrition in the supine pos-
ition have as much as a 50 % incidence of VAP com-
pared to 5 % in those kept in the semirecumbent
position [18]. Therefore, burn patients with maintaining
mechanical ventilation should be kept in the semirecum-
bent position instead of the supine position especially
when administrated with enteral nutrition.
Use of prophylactic antibiotic
In several studies, modulation of oropharyngeal colonization
has also been shown to reduce the incidence of VAP by
using combinations of oral antibiotics, with or without
systemic therapy, or selective decontamination of the
gastrointestinal tract (SDD) [19]. In the areas where the
incidence of VAP is considerablely high, the idea of
prophylactic antibiotics to decrease the incidence is simi-
lar to SDD. Trimethoprim-sulfamethoxazole (TMP-SMX)
Table 1 The clinical pulmonary infection score (CPIS) [36]
Componet Value Points
Temperature C ≥36.5 and ≤38.4 0
≥38.5 and ≤38.9 1
≥39.0 and ≤36.0 2
Blood leukocytes per mm3 ≥4000 and ≤11,000 0
<4000 or >11,000 1




Oxygenation PaO2/FiO2 >240 or presence of ARDS 0
≤240 and absence of ARDS 2
Chest radiograph No infiltrate 0
Pathy or diffuse infiltrate 1
Localized infiltrate 2
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patients which is demonstrated by several researches [20].
However, due to the high endemic levels of antibiotic re-
sistance, the benefits of prophylactic antibiotics for VAP
have been considerablely low in ICUs. In this circum-
stance, prophylactic antibiotics seemed to increase the
selective pressure for antibiotic-resistant microorganisms
resulting in strong resistance of pathogenic bacteria. Thus,
routine prophylactic antibiotics should not be recom-
mended in hospital where there are high levels of antibiotic
resistance, although the use of prophylactic antibiotics can
reduce early-onset VAP.
Reducing oropharyngeal bacterial colonization
Chlorhexidine oral rinse is a simple and cost-effective
prevention strategy for VAP in many different patient
population which has been shown in many studies. A 58 %
reduction in incidences of pneumonia has been found by
Houston et al. [21] in patients intubated>24 h with chlor-
hexidine oral rinse. In critically ill patients ventilated>48 h,
there is also a 65 % reduction in VAP by the same way
[22]. Recently, the use of selective oropharyngeal decon-
tamination (SOD) has been advocated. However, a recent
meta-analysis demonstrated that SOD significantly reduces
the incidence of lower respiratory tract infections but does
not reduce mortality [23].
Restrictive blood transfusion
As we all know, postinjury immunosuppression is con-
sidered as a complication of severe burn injury. Com-
mon therapies can add to the immune compromised
state, such as blood transfusion. Transfusion, which is
demonstrated by several studies, can increased the risk
for VAP [24, 25]. The American Burn Association has
found a 13 % increased risk of infection with each unit
of blood transfused in patients with burn injuries>20 %
TBSA and 42 % of those transfused developed into VAP
[25]. Thus, the restrictive blood transfusion policy should
be applied to burn patients in order to reduce infections.
Intensive insulin therapy
Controlling blood glucose levels (to levels 4.4-6.1mmol/L)
by intensive insulin therapy can decrease mortality in sur-
gical ICU patients which is pulished as a landmark trial in
2001 [26]. However, the subsequent trials did not confirm
this benefit. Recently, Hemmila et al. share their experi-
ences of intensive insulin therapy in burn patients. Their
adoption of protocol (to levels<7.8mmol/L) did decrease
VAP rate with no impact on mortality [27]. The potential
benefit of intensive insulin therapy in burn patients needs
to be confirmed in more large trials. Before that, the
protocol of intensive insulin therapy is an option in burn
patients with ventilation.Control environmental infection
The environment, healthcare devices, and even staff can
all serve as sources of infection. Bacterial colonization of
the ventilator circuit may also lead to VAP. By institu-
tion of an infection control protocol , the U.S. military
has decreased the incidence of VAP in Irap recently,
which includs hand hygiene, chlorhexidine oral care,
contact barrier precautions, patient and staff cohorting,
and reducing the duration and spectrum of surgical anti-
microbial prophylaxis [28].
Diagnosis of VAP
As to the diagnosis, there is no clinical gold standard
existing for the diagnosis of VAP. Many patients with
the clinical diagnosis of pneumonia may have no infec-
tious etiologies, while as many as 66 % of patients with
the clinical diagnosis of VAP did not meet the microbio-
logic criteria for infection. In order to improve the abil-
ity to diagnosis VAP, the scoring systems such as the
U.S. centers for disease control and prevention (CDC)
Criteria and the Clinical Pulmonary Infection Score
(CPIS) have been established, which combine clinical,
radiographic, physiologic (PaO2/FiO2), and microbio-
logic data, to improve the specificity of VAP diagnosis.
An initial score>6 and a persistently elevated CPIS>6
after 3 days of empiric treatment are strongly related to
VAP in mediacal and ICU patients. However, the CPIS
scale is not able to differentiate inflammation from in-
fection, a differentiation that can be definitively made by
quantitative culture (Table 1).
In contrast to the CPIS, it is a recommended strategy
to obtain a lower airway quantitative culture when VAP
is suspected, using broncheoalvolar lavage (BAL), pro-
tected specimen brush, or a nonbronchoscopic technique
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crease specificity of diagnosis and identify the responsible
organisms, and reduce the extended use of broad-
spectrum antimicrobials in the ICU. Most authors use
1*10 5CFU/ml as BAL threshold, however, several studies
in the trauma population have used a BAL threshold of
1*10 5 CFU/ml to limit unnessary administration of sys-
temic antibiotics and rates of VAP recurrence have no
significantly differences. Besides, BAL should not be con-
sidered as 100 % accurate in identifying the infective bac-
terium, but could show good correlation [29].
Treatment of VAP
Early Use of broad-spectrum antibiotic coverage
Many studies have shown that a delay in the initiation of
appropriate antibiotic therapy for patients with VAP has
association with increased morbidity, cost of care, and
mortality whether VAP is early or late in onset [30, 31].
Therefore, once a patient is diagnosed with VAP, broad-
spectrum antibiotic therapy should be adopted immedi-
ately targeting specific likely pathogens based on timing
of VAP onset and modified by knowledge of local pat-
terns of antibiotic resistance. Importantly, a quantitative
culture should be obtained before adoption of antibi-
otics, and diagnostic threshold should be lowed if the
culture is obtained after administration of antibiotics.
De-escalation of broad-spectrum antibiotic
If quantiative culture was obtained, antimicrobial spectrum
should be narrowed according to microbiologic results and
sensitivities, known as de-escalation. Use of ICU specific,
broad-spectrum, empiric therapy is able to lead to a
significant increase in the administration of appropriate
antimicrobial treatment, a decrease in development of
secondary episodes of antibiotic-resistant VAP, and a
significant reduction in the duration of antibiotic treat-
ment [32]. Furthermore, a recent international consen-
sus conference agreed that the use of broad-spectrum
antibiotics for <48h would not induce a significant risk
of multiple drug resistance (MDR).Therefore, de-escalation
of broad-spectrum antibiotic should be adopted as soon as
quantitative culture results are known [33].
Antibiotic rotation
Antibiotic rotation has been evaluated and adopted by
many doctors, although no study has specifically exam-
ined its role in burns. Several evaluation researches have
showed a decreased incidence of MDR bacteria and
mortality benefit with the adoption of antibiotic rotation
[32]. However, antibiotic rotation should be considered
as an option for burn centers to reduce the spread of
MDR bacteria until further burn unit specific data be-
come available.Duration of antibiotic treatment
It is suggested by recent data from many other trails that
antibiotics can be stopped once clinical signs of infection
have resolved. This may also decrease the incidence of
secondary pneumonias with MDR organisms. Dennesen
et al. have reported that most of the clinical signs of
pneumonia have resolved by 6 days of therapy. Another
randomized trial in France demonstrated that there is no
difference in mortality or recurrent infection in patients
treated with an 8 day course of antibiotics compared
with those treated with a 15 day course [34]. Additon-
ally, those treated with 8 days of antibiotics had a lower
incidence of multiresistant pathogens if a recurrent in-
fection developed. Notebly, if the original infecting
organism was a nonlactose fermenting Gram-negative ba-
cilli such as Acinetobacter baumanii, those treated with an
8 day course had a higher pulmonary infection recurrence
rate [35]. Similar to the strong virulence of nonlactose fer-
menting Gram-negative bacilli, MRSA pneumonias are
often quite virulent, with demands for longer ICU and
ventilator support. Thus, unless caused by MRSA or non-
lactose fermenting Gram-nagative rods, in which case the
treatment of 15 day course is recommended, antibiotic
treatment for VAP should be limited with 8 days.Conclusion
Although the research on VAP has made obvious pro-
gress in recent years, there is still no clinical gold
standard existing for the diagnosis of VAP that re-
quires further researched. The recommendations in
these guidelines are derived from available general crit-
ical care and burn literature. Although most of the
data were obtained by study of medical, surgical, and
trauma patients these finding are also applicable to
critically ill burn patients with mechanical ventilation.
Competing interest
The authors declare that they have no competing interests.
Authors’ contribution
LJ searched and organized the literature, and drafted the manuscript. GGH
conceived of the subject and helped to revise the article. Both authors read
and approved the final manuscript.
Received: 1 February 2015 Accepted: 31 May 2015
Published: 31 July 2015
References
1. Mosier MJ, Pham TN. American burn association practice guidelines for
prevention, diagnosis, and treatment of ventilator-associated pneumonia
(VAP) in burn patients[J]. J Burn Care Res. 2009;30(6):910–28.
2. DeRiso AJ, Ladowski JS, Dillon TA, Justice JW, Peterson AC. Chlorhexidine
gluconate 0.12% oral rinse reduces the incidence of total nosocomial
respiratory infection and nonprophylactic systemic antibiotic use in patients
undergoing heart surgery[J]. Chest. 1996;109(6):1556–61.
3. Seguin P, Tanguy M, Laviolle B, Tirel O, Malledant Y. Effect of oropharyngcal
decontamination by povidone-iodine on ventilator-associated pneumonia in
patients with head trauma[J]. Crit Care Med. 2006;34(5):1514–9.
Luo and Guo Burns & Trauma (2015), 3:11 Page 5 of 54. Daniel DS, Ng YK, Chua EL, Arumugam Y, Wong WL, Kumaran JV. Isolation and
identification of gastrointestinal microbiota from the short-nosed friut bat
Cynopterus brachyotis brachyotis[J]. Microbiol Res. 2013;168(8):485–96.
5. Beheshti M, Talebi M, Ardebili A, Ardebili A, Bahador A, Lari AR. Detection of
AdeABC efflux pump genes in tetracycline-resistant Acinebtobacter
baumannii isolates from burn and ventilator-associated pneumonia
patients.[J]. J Pharm Bioallied Sci. 2014;6(4):229–32.
6. Edelman DA, Khan N, Kempf K, White MT. Pneumonia after inhalation
injury[J]. J Burn Car Rehabil. 2007;28(2):241–6.
7. Cox RA, Burke AS, Soejima K, Murakami K, Katahira J, Traber LD, et al.
Airway obstruction in sheep with burn and smoke inhalation injuries[J].
Am J Respir Cell Mol Biol. 2003;29(3):295–302.
8. Virag L. Poly(ADP-ribosyl) ation in asthma and other lung disease[J].
Pharmacol Res. 2005;52(1):83–92.
9. Wunderink RG, Waterer GW. Pneumonia complicating the actue respiratory
distress syndrome[J]. Semin Respir Crit Care Med. 2002;23(5):443–8.
10. Bell RC, Coalson JJ, Smith JD, Johanson WG Jr. Multiple organ system failure
and infection in adult respiratory distress syndrome[J]. Ann Intern Medd.
1983;99(3):293–8.
11. Rubenstein E, Cammarata S, Oliphant T, Wunderink R. Linezolid versus
vancomycin in the treatment of hospitalized patinets with nosocomial
pneumonia:a randomized double-blind multicenter study[J]. Clin Infect Dis.
2001;32:402–12.
12. Heyland DK, Dhaliwal R, Drover JW, Gramlich L, Dodek P. Canadian Critical
Care Clinical Practice Guidelines Committee. Canadian clinical practice
guidelines for nutrition support in mechanically ventilated, critically ill adult
patients[J]. JPEN J Perenter Enteral Nutr. 2003;27(5):355–73.
13. Eckert M, Davis K, Reed RI, Esposito TJ, Santaniello JM, Poulakidas S, et al.
Ventilator-associated pneumonia, like real estate:location really matters[J].
J Trauma. 2006;60(1):104–10.
14. Robertson TE, Sona C, Schallom L, Buckles M, Cracchiolo L, Schuerer D, et al.
Improved extubation rates and carlier liberation from mechanical ventilation
with implementation of a daily spontaneous-breathing trail protocol[J].
J Am Coll Surg. 2008;206:489–95.
15. Ramirez P, Ferrer M, Torres A. Prevention measures for ventilator-associated
pneumonia:a new focus on the endotracheal tube[J]. Curr Opin Infect Dis.
2007;20(2):190–7.
16. Kollef MH, Afessa B, Anzueto A, et al. Sliver-coated endotrachael tubes and
incidence of ventilator-associtated pneumonia:The NASCENT randomized
trial[J]. JAMA. 2008;300(7):805–13.
17. Righi E, Aggazzotti G, Ferrari E, et al. Trends in ventilator-associated
pneumonia:impact of a ventilator care bundle in an Italian tertiary care
hospital intensive care unit[J]. Am J Infect Control. 2014;42(12):1312–6.
18. Correa Rde A, Luna CM, Dos Anjos JC, et al. Quantitative culture of
endotracheal aspirate and BAL fluid samples in the management of
patients with ventilator-associated pneumonia:a randomized clinical trial[J].
J Bras Pneumol. 2014;40(6):643–51.
19. Tanizaki S, Suzuki K. No influence of burn size on ventilator-associated
pneumonia in burn patients with inhalation injury[J]. Burns.
2012;38(8):1109–13.
20. Kimura A, Mochizuki T, Nishizawa K, Mashiko K, Yamamoto Y, Otsuka T.
Trimethoprim-sulframethoxazole for the prevention of methicillin-resistant
Snaphylococcus aureus pneumonia in severely burned patients[J].
J Trauma. 1988;45(2):383–7.
21. Houston S, Hougland P, Anderson JJ, LaRocco M, Kennedy V, Gentry LO.
Effectiveness of 0.12% cholhexidine gluconate oral rinse in reducing
prevalence of nosocomia pneumonia in patients undergoing heart
surgery[J]. Am J Crit Care. 2002;11(6):567–70.
22. Koeman M, van der Ven AJ, Hak E, Joore HC, Kaasjager K, de Smet AG, et al.
Oral decontamination with chlorhexadine reduces the incidence of
ventilator-associated pneumonia[J]. Am J Respir Crit Care Med.
2006;173(12):1348–55.
23. Silvestri L, van Saene HK, Zandstra DF, Viviani M, Gregori D. SDD, SOD or
oropharyngeal chlorhexidine to prevent pneumonia and to reduce
mortality in ventilated patients:which manoeuvre is evidence based?[f].
Intensive Care Med. 2010;36(8):1436–7.
24. Shorr AF, Duh MS, Kelly KM, Kollef MH. Red blood cell transfusion and
ventilator-associated pneumonia:a potential link[J]? Crit Care Med.
2004;32(3):666–74.25. Palmieri TL, Caruso DM, Foster KN, Cairns BA, Peck MD, Gamelli RL, et al.
Effect of blood transfusion on outcome after major burn injury:a multicenter
study[J]. Crit Care Med. 2006;34(6):1602–7.
26. van den Berghc G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz
M, et al. Intensive insulin therapy in the critically ill patients[J]. N Engl J Med.
2001;345(19):1359–67.
27. Hemmila MR, Taddonio MA, Arbabi S, et al. Intensive insulin therapy is
associated with reduced infectious complications in burn patients[J].
Surgery. 2008;144(4):629–35.
28. Landrum ML, Murray CK. Ventialtor associated pneumonia in a military
deployed setting:the impact of an aggressive infection control program[J].
J Trauma. 2008;64(2):123–7.
29. Barret JP, Ramzy PI, Wolf SE, Herndon DN. Sensitivity and specificity of
bronchoalveolar lavage and protected bronchial brush in the diagnosis of
pneumonia in pediatric burn patients[J]. Arch Surg. 1999;134(11):1243–7.
30. Krdzalic A, Kosjerina A, Jahic E, Rifatbegovic Z, Krdzalic G. Influence of
Remifentanil/Propofol Anesthesia on Ventilator-associated Pneumonia
occurence after major cardiac surgery[J]. Med Arch. 2013;67(6):407–9.
31. Huzar TF, Cross JM. Ventilaor –associated pneumonia in burn patients:
acause or consequence of critical illness[J].Expert Rev. Respir Med.
2011;5(5):663–73.
32. Dellit TH, Chan DJ, Skerrett SJ, Nathens AB. Development of a guideline for
the management of ventilator associated pneumonia based on local
microbiolgic findings and impact of the guideline on antimicrobial use
pratices[J]. Infect Control Hosp Epidemiol. 2008;29(6):525–33.
33. Rello J, Paiva JA, Baraibar J, Barcenilla F, Bodi M, Castander D, et al. International
conference for the development of consensus on the diagnosis and treatment
of ventilator-associated pneumonia[J]. Chest. 2001;120(3):955–70.
34. Dennesen PJ, Van der Ven AJ, Kessels AG, Ramsay G, Bonten M. Resolution
of infectious parameters after microbial therapy in patients with ventilator-
associated pneumonia[J]. Am J Respir Crit Care Med. 2001;163(6):1371–5.
35. Mc Govern Murphy F, Raymond M, Menard PA, Bejar-Ardiles KR, Carignan A,
Lesur O. Ventilator associated pneumonia and endotracheal tube
repositioning: an underrated risk factor[J]. Am J Infect Control.
2014;42(12):1328–30.
36. Schurink CA, Van Nieuwenhoven CA, Jacobs JA, Rozenberg-Arska M, Joore HC,
Buskens E, et al. Clinical pulmonary infection score for ventilator-associated
pneumonia:accuracy and inter-observer variability[J]. Intensive Care Med.
2004;30(2):217–24.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
